Last reviewed · How we verify

NCT06583005

Vibrotactile Coordinated Reset for Parkinsons Patients Who Are on Dopaminergic Medication

Not yet recruiting NA Last updated 3 September 2024
What this trial tests

NA trial testing Vibrotactile Coordinated Reset in Parkinson Disease, Idiopathic in 20 participants. Not yet recruiting.

Timeline
15 February 2025
Primary endpoint
15 May 2027
15 May 2027

Quick facts

Lead sponsorStanford University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date15 February 2025
Primary completion15 May 2027
Estimated completion15 May 2027

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

18 and older, female only, with Parkinson Disease, Idiopathic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to test the efficacy of vibrotactile coordinated reset stimulation to improve movement ability and other symptoms of human subject participants with Parkinsons Disease who take dopaminergic medication and are unable to withhold this medication. Participants will be followed for five years and make a total of five study visits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vibrotactile Coordinated Reset

Trials testing the same drug.

Other recruiting trials for Parkinson Disease, Idiopathic

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06583005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing